FGFR2/CD332 Antibody, Unconjugated, Monoclonal

Artikelnummer: BYT-ORB1806350
Artikelname: FGFR2/CD332 Antibody, Unconjugated, Monoclonal
Artikelnummer: BYT-ORB1806350
Hersteller Artikelnummer: orb1806350
Alternativnummer: BYT-ORB1806350-1,BYT-ORB1806350-100
Hersteller: Biorbyt
Kategorie: Antikörper
Applikation: ELISA, FA, FACS, In vivo
Spezies Reaktivität: Human
Konjugation: Unconjugated
Anti-FGFR2 / CD332 Reference Antibody is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.24 kDa.
Klonalität: Monoclonal
Konzentration: Batch dependent
Molekulargewicht: 144 kDa
UniProt: P21802
Puffer: 100 mM Proline/Acetic acid 20mM Arginine pH 5.0
Reinheit: >95%
Target-Kategorie: FGFR2 / CD332
Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab)is more than 100% ,determined by SEC-HPLC.
SNU-16 cells were stained with Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC763=0.5368 µg/mL.
Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) induced ADCC activity was evaluated using Human FGFR2 HEK293 Reporter Cell.The max induction fold was approximately 25.
Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) -ADCC luciferase Assay on KATOIII cells. The maximum suppression factor is approximately 14.
Bemarituzumab inhibited the tumor growth of SNU-16 on Balb/c nude mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 29.7% at 2 mpk at D62.